Shares of Novavax (NASDAQ:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, tumbled nearly 17% during Thursday’s pre-market …
Wall Street is paying attention to FBR’s George Zavoico’s surge in enthusiasm on Novavax’s prospects.
Cantor’s William Tanner is not thrilled as he joins a disgruntled Street saying goodbye to what could have been a meaningful catalyst for NVAX shares before the end of 2017: NanoFlu vaccine top-line data.
Novavax, Inc. (NASDAQ:NVAX) announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal …
Novavax, Inc. (NASDAQ:NVAX) announced that Barclay A.
Novavax Shares Pop 6% on Preclinical Influenza Nanoparticle Data
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the second quarter and six months ended June 30, 2017.
FBR analyst Vernon Bernardino met with Novavax, Inc. (NASDAQ:NVAX) management last week to discuss fundamentals and future 2017 clinical development.
Tesla Motors Inc (NASDAQ:TSLA) jumped 2.57% in pre-market trading after the electric auto-maker received an Outperform rating and by Oppenheimer analyst Colin Rusch …
Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced the appointment …
